Antiviral Compounds Formula I for Broad-Spectrum Viral Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for influenza and measles virus infections are inadequate, with existing vaccines and antiviral drugs offering limited protection and efficacy, particularly in vulnerable populations and against diverse viral strains.
Innovation Solution
Development of pharmaceutical compositions containing specific antiviral compounds, such as those represented by Formula I, which are administered alone or in combination with other antiviral agents to treat or prevent infections caused by RNA and DNA viruses, including influenza and measles viruses, with improved solubility and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current influenza vaccines are used, then protection is provided for healthy adults, but protection efficacy is reduced in the elderly and when circulating strains differ from vaccine strains
Solution Approach 1:
The patent modifies the chemical structure of known antiviral compounds by changing parameters such as substituting hydrogen atoms with fluorine, adding methyl groups, or altering functional groups to create analogs with improved potency and spectrum of activity against multiple viral strains and species
Solution Approach 2:
The patent develops broad-spectrum antiviral compounds that are effective against multiple virus types including influenza A and B, respiratory syncytial virus, and other paramyxoviruses, providing universal protection across different viral threats and host species
2Duration of action of moving object
If Oseltamivir is administered early in influenza infection, then mild benefits in symptom duration are achieved, but it does not prevent lower respiratory tract infections or other complications
Solution Approach 1:
The patent creates compound analogs with modified chemical parameters that enhance antiviral potency and cellular penetration, enabling the drugs to achieve effective intracellular concentrations that prevent viral replication and complications rather than merely shortening symptom duration
3Reliability
If Ribavirin is used for paramyxovirus infections, then some treatment effect is achieved, but efficacy is limited and additional agents are needed
Solution Approach 1:
The patent develops new chemical analogs with modified structures that improve upon Ribavirin's limitations by enhancing potency, reducing required dosages, and expanding activity to include influenza viruses and other paramyxoviruses not effectively covered by Ribavirin
Solution Approach 2:
The patent creates composite pharmaceutical formulations combining the new antiviral compounds with excipients and delivery systems that enhance solubility, bioavailability, and therapeutic effectiveness while reducing side effects
Data Source
AI summary
This disclosure relates to antiviral compounds disclosed herein and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions. Typically, the pharmaceutical composition comprises a compound of formula I:or salt, prodrug, or ester thereof wherein X, Y, and R1 and R10 to R13 are described herein.